Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

Part of paid clinical trials in Denver, Colorado.

Sponsor
National Jewish Health
Study ID
NCT02947945
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Reslizumab — DRUG
    All subjects will receive Reslizumab

Study Details

Reslizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5. The study medicine, reslizumab, is not yet approved for doctors to treat patients with EGPA. It is considered an experimental drug in this study.

Key Dates

Start date
Sep 12, 2017
Status verified
Sep 2017
Primary completion
Dec 31, 2018
Completion
Dec 31, 2018

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Open-Label
    all subjects will receive the study medication- reslizumab.

Primary Outcome Measure

Document the safety of reslizumab therapy in patients with EGPA [ Time Frame: up to 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
National Jewish HealthDenverColorado80206
Michael Wechsler, MD
[email protected]
303-398-1085

Find similar trials in Denver, CO

By condition
Asthma
By specialty
PulmonologyLung disease
By research site
National Jewish Health· Denver, CO

Related Studies